KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $29.40 Consensus Target Price from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $29.40.

Several analysts have weighed in on KALV shares. HC Wainwright upped their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Needham & Company LLC lifted their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th.

KalVista Pharmaceuticals Stock Performance

KALV opened at $16.94 on Friday. KalVista Pharmaceuticals has a 1-year low of $9.23 and a 1-year high of $19.00. The stock has a market cap of $856.32 million, a P/E ratio of -4.29 and a beta of -0.35. The stock’s 50 day simple moving average is $15.76 and its 200 day simple moving average is $14.27. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Nicole Sweeny sold 3,975 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $61,890.75. Following the completion of the transaction, the insider directly owned 47,003 shares of the company’s stock, valued at $731,836.71. This trade represents a 7.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Paul K. Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the transaction, the insider owned 138,983 shares of the company’s stock, valued at $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 33,378 shares of company stock valued at $522,290 over the last three months. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Emerald Advisers LLC increased its position in KalVista Pharmaceuticals by 30.2% during the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after purchasing an additional 313,205 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $3,494,000. Blue Owl Capital Holdings LP purchased a new position in KalVista Pharmaceuticals in the 3rd quarter valued at about $1,522,000. Stonepine Capital Management LLC boosted its stake in shares of KalVista Pharmaceuticals by 364.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $1,130,000 after purchasing an additional 78,450 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust boosted its stake in shares of KalVista Pharmaceuticals by 19.4% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 917,975 shares of the specialty pharmaceutical company’s stock worth $11,181,000 after purchasing an additional 149,003 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.